248 related articles for article (PubMed ID: 30654737)
1. Origin and diversification of the plasminogen activation system among chordates.
Chana-Muñoz A; Jendroszek A; Sønnichsen M; Wang T; Ploug M; Jensen JK; Andreasen PA; Bendixen C; Panitz F
BMC Evol Biol; 2019 Jan; 19(1):27. PubMed ID: 30654737
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains.
Bager R; Kristensen TK; Jensen JK; Szczur A; Christensen A; Andersen LM; Johansen JS; Larsen N; Baatrup E; Huang M; Ploug M; Andreasen PA
J Biol Chem; 2012 Aug; 287(33):27526-36. PubMed ID: 22733817
[TBL] [Abstract][Full Text] [Related]
3. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
[TBL] [Abstract][Full Text] [Related]
4. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
[TBL] [Abstract][Full Text] [Related]
5. A kringle-containing protease with plasminogen-like activity in the basal chordate Branchiostoma belcheri.
Liu M; Zhang S
Biosci Rep; 2009 Sep; 29(6):385-95. PubMed ID: 19193194
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and structural analyses suggest that plasminogen activators coevolved with their cognate protein substrates and inhibitors.
Jendroszek A; Madsen JB; Chana-Muñoz A; Dupont DM; Christensen A; Panitz F; Füchtbauer EM; Lovell SC; Jensen JK
J Biol Chem; 2019 Mar; 294(10):3794-3805. PubMed ID: 30651349
[TBL] [Abstract][Full Text] [Related]
8. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
9. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
Sipley JD; Alexander DS; Testa JE; Quigley JP
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
[TBL] [Abstract][Full Text] [Related]
10. The structure, splicing, synteny and expression of lamprey COE genes and the evolution of the COE gene family in chordates.
Lara-Ramírez R; Poncelet G; Patthey C; Shimeld SM
Dev Genes Evol; 2017 Sep; 227(5):319-338. PubMed ID: 28871438
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
[TBL] [Abstract][Full Text] [Related]
12. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
13. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
14. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Sirén V; Antinheimo JP; Jääskeläinen J; Böhling T; Carpén O; Vaheri A
Acta Neurochir (Wien); 2004 Feb; 146(2):111-8. PubMed ID: 14963743
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways.
Schnaper HW; Barnathan ES; Mazar A; Maheshwari S; Ellis S; Cortez SL; Baricos WH; Kleinman HK
J Cell Physiol; 1995 Oct; 165(1):107-18. PubMed ID: 7559792
[TBL] [Abstract][Full Text] [Related]
17. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
Behrendt N; List K; Andreasen PA; Danø K
Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
[TBL] [Abstract][Full Text] [Related]
18. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Wang Q; Shaltiel S
BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
[TBL] [Abstract][Full Text] [Related]
19. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
[TBL] [Abstract][Full Text] [Related]
20. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]